The first drugs for Alzheimer’s disease emerged in the 1990s, but since then there has been a wave of clinical trial failures, major companies pulling resources from neuroscience R&D, and progress.
A fascinating study in Europe finds that individuals who felt they had memory problems did in fact have measurable cognitive deficits. Scientists analyzed the spinal fluid to measure the levels of biomarkers associated with Alzheimer’s.
Swedish researchers find that cholinesterase inhibitors provide cognitive benefits and reduce mortality for up to five years after an Alzheimer’s diagnosis. One medication significantly reduced the risk of developing severe dementia.
Swiss researchers find that people with certain personality traits are protected against Alzheimer’s disease, including those who are less agreeable, had natural curiosity, and were nonconformists. Find out why.
Researchers in Florida find that robotic pet cats improve mood, behavior and cognition in older adults with mild to moderate dementia. Find out more.
Dr. Robert Przybelski has prescribed lecanemab to real-life patients, and discusses his experience prescribing and administering the treatment.
Scientists say restoring a brain protein, not removing amyloid plaques, should be the target of Alzheimer’s dementia therapies. The researchers said treatment might lie in normalizing the levels of a specific brain protein.
Now, a third new Alzheimer’s drug expected to be approved by the Food and Drug Administration (FDA),. The field of new drugs is beginning to show progress in the fight to slow the disease.
Researchers found in a study that people who developed dementia were more likely to have their credit rating drop at least two and a half years before the diagnosis. Some had problems managing their money up to six years before. Find out more.
The FDA has approved generic lecanemab (brand name Leqembi®). The new drug can slow the progression of Alzheimer’s. Two top doctors discuss the pros and cons.
See why Leqembi is even more effective in males than females, at fighting Alzheimer’s.
Stanford Medicine’s new analysis of a vaccination program found shingles vaccines appear to lower dementia diagnoses by 20% — more than any other known intervention.
The big Alzheimer’s culprits are Amyloid and Tau. Biogen made Leqembi to treat amyloid. Now, they are betting on BIIB080 to treat tau. Learn how this exciting new treatment just got FDA Fast Track Designation.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.
